Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
E: investor.relations@roche.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
103,605
Roche Holding AG News & Analysis
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
stocks
5 top US dividend shares from the best managers
These cheap dividend stocks are popular among highly rated concentrated fund managers.
stocks
10 best US blue-chip shares to buy for the long term
The stocks of these high-quality companies with large market capitalizations look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,344.80 | 77.30 | -0.92% |
| CAC 40 | 7,350.37 | 77.99 | -1.05% |
| DAX 40 | 19,077.54 | 179.80 | -0.93% |
| Dow JONES (US) | 41,763.46 | 378.08 | -0.90% |
| FTSE 100 | 8,110.10 | 49.53 | -0.61% |
| HKSE | 20,317.33 | 63.31 | -0.31% |
| NASDAQ | 18,095.15 | 512.78 | -2.76% |
| Nikkei 225 | 39,081.25 | 196.14 | -0.50% |
| NZX 50 Index | 12,579.18 | 59.72 | -0.47% |
| S&P 500 | 5,705.45 | 108.22 | -1.86% |
| S&P/ASX 200 | 8,083.80 | 76.20 | -0.93% |
| SSE Composite Index | 3,279.82 | 13.59 | 0.42% |